Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/08/2878243/0/en/Context-Therapeutics-Reports-First-Quarter-2024-Operating-and-Financial-Results.html
https://www.globenewswire.com/news-release/2024/05/02/2874098/0/en/Context-Therapeutics-Announces-FDA-Clearance-of-IND-Application-for-a-Phase-1-Clinical-Trial-of-CTIM-76.html
https://www.globenewswire.com/news-release/2024/05/02/2874089/0/en/Context-Therapeutics-Announces-100-Million-Private-Placement.html
https://www.globenewswire.com/news-release/2024/04/01/2855097/0/en/Context-Therapeutics-Submits-IND-Application-to-Evaluate-CTIM-76-in-Claudin-6-Positive-Cancers.html
https://www.globenewswire.com/news-release/2024/03/21/2850147/0/en/Context-Therapeutics-Reports-Full-Year-2023-Operating-and-Financial-Results.html
https://www.globenewswire.com//news-release/2023/11/09/2777887/0/en/Context-Therapeutics-Reports-Third-Quarter-2023-Operating-and-Financial-Results.html
https://www.globenewswire.com//news-release/2023/10/31/2770270/0/en/Context-Therapeutics-Announces-Preclinical-Data-Demonstrating-Differentiated-and-Active-Profile-of-its-Claudin-6-Targeted-Bispecific-Antibody-CTIM-76.html
https://www.globenewswire.com//news-release/2023/09/27/2750426/0/en/Context-Therapeutics-Announces-Acceptance-of-Abstract-to-be-Presented-at-the-Society-for-Immunotherapy-of-Cancer-s-SITC-38th-Annual-Meeting.html
https://www.globenewswire.com/news-release/2023/08/09/2722147/0/en/Context-Therapeutics-Reports-Second-Quarter-2023-Operating-and-Financial-Results.html
https://www.globenewswire.com/news-release/2023/08/01/2715694/0/en/Context-Therapeutics-to-Participate-in-Two-August-2023-Investor-Conferences.html